CDKN1C/p57 Cancer Research Results

CDKN1C/p57, cyclin-dependent kinase (CDK) inhibitors of the Cip/Kip family: Click to Expand ⟱
Source:
Type:
CDKN1C(p57 KIP2)
CDKN1C, also known as p57^KIP2, is a cyclin-dependent kinase inhibitor that plays a role in regulating the cell cycle.
Decreased expression of CDKN1C is often associated with more aggressive tumor behavior, increased invasiveness, and poorer prognosis across various cancer types.
Scientific Papers found: Click to Expand⟱
2784- CHr,    Chrysin targets aberrant molecular signatures and pathways in carcinogenesis (Review)
- Review, Var, NA
Apoptosis↑, TumCMig↓, *toxicity↝, ChemoSen↑, *BioAv↓, Dose↝, neuroP↑, *P450↓, *ROS↓, *HDL↑, *GSTs↑, *SOD↑, *Catalase↑, *MAPK↓, *NF-kB↓, *PTEN↑, *VEGF↑, ROS↑, MMP↓, Ca+2↑, selectivity↑, PCNA↓, Twist↓, EMT↓, CDKN1C/p57↑, p‑STAT3↑, MMP2↓, MMP9↓, Synergy↑, cycD1/CCND1↓, hTERT/TERT↓, CLDN1↓, TumVol↓, OS↑, COX2/PTGS2↓, Synergy↑, CDK2↓, CDK4↓, selectivity↑, TumCCA↑, E-cadherin↑, HK2↓, HDAC↓,
8845- DIM,  I3C,    3,3′-Diindolylmethane and indole-3-carbinol: potential therapeutic molecules for cancer chemoprevention and treatment via regulating cellular signaling pathways
- Review, Var, NA
*BioAv↝, *BioAv↓, *BioAv↓, *AntiAg↑, *ROS↓, *AntiThr↑, *Stroke↓, *CYP1A1↑, *CYP1A2↑, *GSTs↑, *NQO1↑, AntiTum↑, AntiCan↑, TumAuto↓, Let-7↑, miR-34a↑, TumCMig↓, Apoptosis↑, MMP↓, mtDam↑, ROS↑, TumCCA↑, other↝, PSA↓, Dose↝, MMP2↓, MMP3↓, MMP9↓, EGFR↓, RAS↓, PI3K↓, Akt↓, mTOR↓, CDK4↓, cycD1/CCND1↓, P21↑, MDM2↓, TumCP↓, NF-kB↓, RANKL↓, PUMA↓, Wnt↓, MTA2↓, EZH2↓, AhR↓, PTEN↑, NOTCH1↓, IRAK1↓, p27/CDKN1B↓, CDKN1C/p57↓, CDC25↓, EGFR↓, Zeb1↓, FOXM1↓, SOX4↓, E-cadherin↑, uPA↓, uPAR↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 2,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC25↓, 1,   mtDam↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

HK2↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 2,   MDM2↓, 1,   PUMA↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 1,   EGFR↓, 2,   mTOR↓, 1,   PI3K↓, 1,   PTEN↑, 1,   RAS↓, 1,   p‑STAT3↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

EZH2↓, 1,   FOXM1↓, 1,   HDAC↓, 1,   miR-34a↑, 1,   MTA2↓, 1,   other↝, 1,   SOX4↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

hTERT/TERT↓, 1,   PCNA↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 2,   CDKN1C/p57↓, 1,   CDKN1C/p57↑, 1,   cycD1/CCND1↓, 2,   P21↑, 1,   p27/CDKN1B↓, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Let-7↑, 1,   NOTCH1↓, 1,   TumCP↓, 1,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

Ca+2↑, 1,   E-cadherin↑, 2,   EMT↓, 1,   MMP2↓, 2,   MMP3↓, 1,   MMP9↓, 2,   TumCMig↓, 2,   Twist↓, 1,   uPA↓, 1,   uPAR↓, 1,   Zeb1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

CLDN1↓, 1,   MMP↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IRAK1↓, 1,   NF-kB↓, 1,   PSA↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AhR↓, 1,   RANKL↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Dose↝, 2,   selectivity↑, 2,   Synergy↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 2,   EZH2↓, 1,   FOXM1↓, 1,   hTERT/TERT↓, 1,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   neuroP↑, 1,   OS↑, 1,   TumVol↓, 1,  
Total Targets: 69

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↑, 1,   GSTs↑, 2,   HDL↑, 1,   NQO1↑, 1,   ROS↓, 2,   SOD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

MAPK↓, 1,   PTEN↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

VEGF↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

NF-kB↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   BioAv↝, 1,   CYP1A1↑, 1,   CYP1A2↑, 1,   P450↓, 1,  

Functional Outcomes(tgid=23) ⓘ

Stroke↓, 1,   toxicity↝, 1,  
Total Targets: 19

Scientific Paper Hit Count for: CDKN1C/p57, cyclin-dependent kinase (CDK) inhibitors of the Cip/Kip family
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:496  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page